Experimental treatment slows prion disease, extends life of mice

Scientists using an experimental treatment have slowed the progression of scrapie, a degenerative central nervous disease caused by prions, in laboratory mice and greatly extended the rodents’ lives. The scientists used antisense oligonucleotides (ASOs), synthetic compounds that inhibit the formation of specific proteins.

Prion protein, shown in red, can become infectious and cause neurodegenerative disease. Here four nerve cells in a mouse illustrate how infectious prion protein moves within cells along neurites – wire-like connections the nerve cells use for communicating with adjacent cells. Photo: NIAID

Prion diseases occur when normally harmless prion protein molecules become abnormal and gather in clusters and filaments in the body, including the brain. The diseases are thought to be always fatal. Scrapie, which affects sheep and goats and can be adapted to rodents, is closely related to human prion diseases such as Creutzfeldt-Jakob disease, which is currently untreatable. Thus, scrapie is a valuable experimental model for the development of human prion disease therapies.

In the studies, scientists injected ASOs into the spinal fluid of mice already infected with scrapie or that were challenged with scrapie proteins within weeks of the injection. Ionis Pharmaceuticals specifically designed ASO1 and ASO2 to reduce the rodents’ supply of normal prion protein.

RML scientists injected either ASO1 or ASO2 into mice 14 days prior to infecting them with scrapie, and then seven or 15 weeks after infection. Mice treated with ASO1 did not show clinical signs of disease for a median 250 days, or 82% longer than untreated mice (137 days), and they lived 81% longer than untreated mice (259 days versus 143 days).

Mice treated with ASO2 did not show clinical signs of disease for a median 272 days, or 99% longer than untreated mice (137 days), and they lived 98% longer than untreated mice (283 days versus 143 days).

In the Broad Institute experiments, mice received either ASO1 or ASO2 2 weeks before infection with scrapie and then seven weeks after infection. Both ASOs delayed rodent weight loss. Mice treated with ASO1 and ASO2 both lived longer than untreated mice, by 61% (274 days versus 170 days) and 76% (300 days versus 170 days), respectively.

The RML group also tested the ASOs against established prion disease, treating mice 17 weeks after they were infected with scrapie – near the onset of clinical signs. Mice treated with ASO1 did not show signs of clinical disease for a median 189 days, or 33% longer than untreated mice (142 days).

They also showed slower disease progression and lived 55% longer than untreated mice (244 days versus 157 days). ASO2 had no beneficial effect. (National Institutes of Health)

YOU MAY ALSO LIKE

Study Shows Chemotherapy Not Needed To Treat Many Breast Cancers

After a diagnosis of breast cancer, many women have surgery followed by chemotherapy and radiation. But a new study shows that if the cancer is caught early enough, women might be able to avoid the chemotherapy.

Acute kidney injury, chronic kidney disease each a risk of the other

Acute kidney injury and chronic kidney disease are closely intertwined, with each disease a risk factor for developing the other and sharing other risk factors in common, as well as sharing causes for the diseases to get worse, and outcomes, suggests a comprehensive analysis.

Moderate Carbohydrate Intake May be Best for Health

A new study has found that diets both low and high in carbohydrates were linked with an increase in mortality, while moderate consumers of carbohydrates had the lowest risk of mortality.

Structural Snapshots of Damaged DNA

Researchers revealed how nucleotides damaged by oxidative stress become inserted into DNA strands and block DNA repair mechanisms. The cell death triggered by this process is thought to play a role in many diseases.

New Approach to Pancreatic Cancer Screening May Help Catch Disease Earlier

A new approach to pancreatic cancer screening may help doctors detect the disease in people at high risk before it reaches more advanced and difficult-to treat stages.

Multiple Sclerosis Treatment Developed in Australia Shows Promise

Australian researchers have made a breakthrough in the treatment of Multiple Sclerosis using immunotherapy. Their world-first trial has produced promising results for the majority of patients enrolled, they said, including a reduction in fatigue and improvements in mobility and vision.